Results 131 to 140 of about 681,456 (227)

Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +1 more source

Impact on hospitals of price reductions for physician-administered biologics. [PDF]

Health Aff Sch
Robinson JC, Thomson M, Kosorukov AD, Whaley CM.   +3 more
europepmc   +1 more source

Shaping the future of retinal care in India: Anti-VEGF therapy now and beyond. [PDF]

Indian J Ophthalmol
Karpe A, Narula R, Shroff D, Roy A.
europepmc   +1 more source

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]

Biologics
Ranbhor R, Kulkarni P.
europepmc   +1 more source

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Fenwick S, Parekh V, Shah N, Patel R, Kale P, Kolte S.   +5 more
europepmc   +1 more source

Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

Eye, 2019
Ashish Sharma, M. Hafeez Faridi, Nilesh Kumar, N. Parachuri, Rohini Sharma, B. Kuppermann, F. Bandello, A. Loewenstein, C. Regillo   +8 more
semanticscholar   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Short-term efficacy and safety of infliximab biosimilar (HS626) in inducing remission of inflammatory bowel disease: A real-world single-center study. [PDF]

Medicine (Baltimore)
Huang YS, Lai DP, Nong H, Zhang T, Chen ZY, Zeng WB, Huang XP, Lin YY.   +7 more
europepmc   +1 more source

Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]

J Manag Care Spec Pharm
Dayer VW, Hansen RN, Roth J, Jofre-Bonet M, Sullivan SD.   +4 more
europepmc   +1 more source

Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study). [PDF]

Clin Ophthalmol
Chakraborty S, Sheth JU, Ganguly S, Reddy P.   +3 more
europepmc   +1 more source